Yukon Immunization Program Manual

Section 8 - Biological Products

Rotavirus Vaccine

SECTION 8 – BIOLOGICAL PRODUCTS

Contents

	2019 August
Rotavirus Vaccine (Human rotavirus, live attenuated, oral vaccine) RotaTeq® **Supplier: Merck Canada Inc., RotaTeq®**	
INDICATIONS	**INITIAL SERIES ❶❷❸❹❺❻❼❽**
For routine immunization of infants beginning at 2 months age. Series must be completed by 8 months of age.	3 doses given as 2.0 mL by mouth at 2, 4, and 6 months of age.
ADMINISTRATION	• Give entire contents of applicator. • If infant spits out or regurgitates any of the vaccine dose, no replacement dose should be administered.
REINFORCEMENTS	No booster doses are recommended at this time.
CONTRAINDICATIONS	1. History of anaphylactic reaction to a previous dose of rotavirus vaccine, or to any component of RotaTeq® 2. Infants with a history of intussusception. 3. Infants with a suspected or known immunocompromising condition should not receive rotavirus vaccine without consultation with a physician specialist or expert in the condition. 4. Infants diagnosed with Severe Combined Immunodeficiency (SCID.) 5. Uncorrected congenital gastrointestinal conditions (e.g., Meckel's diverticulum.)
PRECAUTIONS	1. Acute gastroenteritis: in infants with *moderate to severe* gastroenteritis, rotavirus vaccine should be deferred until the condition improves unless deferral will result in scheduling of the first dose at more than 20 weeks less 1 day of age. Infants with *mild* gastroenteritis can be vaccinated. 2. Pre-existing chronic gastrointestinal conditions: the safety and efficacy of rotavirus vaccines has not been established in children with pre-existing chronic gastrointestinal disease. However, infants with chronic gastrointestinal disease who are not receiving immunosuppressive therapy are likely to benefit from rotavirus vaccination and therefore can be vaccinated.
VACCINE COMPONENTS	**Potential allergens:** fetal bovine serum, polysorbate 80. **Other components:** sucrose, sodium citrate dehydrate, sodium phosphate monobasic monohydrate, sodium hydroxide, porcine circovirus types 1 and 2.

	2019 August
Rotavirus Vaccine (Human rotavirus, live attenuated, oral vaccine)RotaTeq® **Supplier: Merck Canada Inc., RotaTeq®**	
ADVERSE EVENTS	RotaTeq®: **Local**: diarrhea, abdominal pain (<1%), flatulence (<1%). **Systemic**: dermatitis (<1%), irritability. A small increased risk of intussusception of between 1 and 7 cases per 100,000 doses in the 7 days following both the first and second doses (as per CIG).

❶ Preterm infants who are healthy and not hospitalized can receive rotavirus vaccine.
❷ Infants who have had rotavirus gastroenteritis before receiving the full course of vaccinations should still initiate or complete the rotavirus vaccine schedule because the initial infection frequently provides only partial immunity.
❸ RotaTeq®, max age for first dose is 5 months less a day of age; Rotarix®, max age for first dose is 5 months less 1 day of age.
❹ There should be a minimum interval of 4 weeks between doses.
❺ All doses should be administered by 8 months of age.
❻ There are no restrictions on the infant's consumption of food or liquid, including breast milk, either before or after vaccination.
❼ Rotavirus vaccine may be administered at any time before, concurrently with, or after administration of any blood product, including antibody-containing products.
❽ There are no data on the interchangeability of RotaTeq® and Rotarix® vaccines. Whenever possible, the series should be completed with the same product. However, if the product used for a previous dose(s) is not known, complete the series with the available product. If any dose in the series was RotaTeq®, a total of 3 doses of vaccine should be administered.